Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2014

Filed with the SEC on Dec 15, 2014 and accepted by EDGAR at Dec 15, 2014, 16:50 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-10-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-08-01 to 2014-10-31$0us-gaap:Revenues
Revenue6 months2014-05-01 to 2014-10-31$0us-gaap:Revenues
Cost of revenue3 months2014-08-01 to 2014-10-31$0us-gaap:CostOfRevenue
Cost of revenue6 months2014-05-01 to 2014-10-31$0us-gaap:CostOfRevenue
Gross profit3 months2014-08-01 to 2014-10-31$0us-gaap:GrossProfit
Gross profit6 months2014-05-01 to 2014-10-31$0us-gaap:GrossProfit
Research and development3 months2014-08-01 to 2014-10-31$347.8kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2014-05-01 to 2014-10-31$347.8kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2014-08-01 to 2014-10-31−$6.2mus-gaap:OperatingIncomeLoss
Operating income6 months2014-05-01 to 2014-10-31−$7.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2014-08-01 to 2014-10-31$2.1kus-gaap:InterestExpense
Interest expense6 months2014-05-01 to 2014-10-31$4.7kus-gaap:InterestExpense
Net income3 months2014-08-01 to 2014-10-31−$4.1mus-gaap:NetIncomeLoss
Net income6 months2014-05-01 to 2014-10-31−$5.6mus-gaap:NetIncomeLoss
Basic EPS3 months2014-08-01 to 2014-10-31−$0.01us-gaap:EarningsPerShareBasic
Basic EPS6 months2014-05-01 to 2014-10-31−$0.01us-gaap:EarningsPerShareBasic
Operating cash flow6 months2014-05-01 to 2014-10-31−$2.2mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2014-10-31$1.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-10-31$1.3mus-gaap:AssetsCurrent
Total assetsAt period end2014-10-31$6.7mus-gaap:Assets
Current liabilitiesAt period end2014-10-31$276.9kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-10-31$276.9kus-gaap:Liabilities
Shareholders' equityAt period end2014-10-31$6.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001019687-14-004716. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.